General Biologicals Corporation
General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening… Read more
General Biologicals Corporation (4117) - Total Liabilities
Latest total liabilities as of June 2025: NT$3.38 Billion TWD
Based on the latest financial reports, General Biologicals Corporation (4117) has total liabilities worth NT$3.38 Billion TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
General Biologicals Corporation - Total Liabilities Trend (2019–2024)
This chart illustrates how General Biologicals Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
General Biologicals Corporation Competitors by Total Liabilities
The table below lists competitors of General Biologicals Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Raubex
JSE:RBX
|
South Africa | ZAC8.63 Billion |
|
Sidomulyo Selaras Tbk
JK:SDMU
|
Indonesia | Rp116.09 Billion |
|
FASING SA
WAR:FSG
|
Poland | zł178.02 Million |
|
Lixiang Education Holding Co Ltd
NASDAQ:LXEH
|
USA | $28.10 Million |
|
Bank Utica Ny Nonvtg
PINK:BKUTK
|
USA | $744.38 Million |
|
Jerusalem
TA:JBNK
|
Israel | ILA20.63 Billion |
|
Bodhi Tree Multimedia Limited
NSE:BTML
|
India | ₹528.05 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down General Biologicals Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 21.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how General Biologicals Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for General Biologicals Corporation (2019–2024)
The table below shows the annual total liabilities of General Biologicals Corporation from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$3.12 Billion | +52.85% |
| 2023-12-31 | NT$2.04 Billion | +137.98% |
| 2022-12-31 | NT$857.51 Million | +61.86% |
| 2021-12-31 | NT$529.79 Million | +264.02% |
| 2020-12-31 | NT$145.54 Million | -30.51% |
| 2019-12-31 | NT$209.43 Million | -- |